Nxera Pharma Co., Ltd.
4565.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | ¥94 | ¥117 | ¥175 | ¥155 |
| - Cash | ¥32 | ¥49 | ¥67 | ¥60 |
| + Debt | ¥68 | ¥74 | ¥30 | ¥29 |
| Enterprise Value | ¥130 | ¥142 | ¥138 | ¥124 |
| Revenue | ¥29 | ¥13 | ¥16 | ¥18 |
| % Growth | 125.9% | -18% | -12.1% | – |
| Gross Profit | ¥21 | ¥10 | ¥15 | ¥17 |
| % Margin | 73.6% | 75.7% | 94.1% | 94.7% |
| EBITDA | ¥0 | -¥6 | ¥4 | ¥2 |
| % Margin | 0.4% | -44.7% | 22.9% | 12.4% |
| Net Income | -¥5 | -¥7 | ¥0 | ¥1 |
| % Margin | -16.8% | -56.3% | 2.5% | 5.7% |
| EPS Diluted | -53.92 | -87.17 | 4.63 | 12.4 |
| % Growth | 38.1% | -1,982.7% | -62.7% | – |
| Operating Cash Flow | -¥8 | -¥5 | ¥10 | ¥7 |
| Capital Expenditures | -¥1 | -¥1 | -¥0 | -¥0 |
| Free Cash Flow | -¥8 | -¥6 | ¥10 | ¥7 |